James E. Tisdale
Residency, Pharmacy Practice, University of Manitoba Health Sciences Centre, 1984
PharmD, State University of New York at Buffalo, 1988
Fellowship, Cardiovascular Therapeutics, Hartford Hospital & University of Connecticut, 1988-1990
Jim's research interests are in the area of cardiovascular pharmacotherapy, focusing on: mechanisms, risk factors, and management of drug-induced arrhythmias, and drug therapy for prevention and treatment of atrial fibrillation. His research has resulted in the publication of over 160 journal articles, chapters and research abstracts. Jim is the co-editor of the book entitled, "Drug-Induced Diseases. Prevention, Detection and Management," the 3rd edition of which will be published in 2018. Jim's research is currently funded by the American Heart Association (AHA), and has been funded by the Heart Rhythm Society, the Indiana Clinical Translational Sciences Institute Strategic Research Initiative and the American College of Clinical Pharmacy (ACCP). From 2001-2004 and 2008-2011, Jim was a member of the Board of Regents of ACCP, and from 2008-2009 he was Chair, Clinical Sciences Section, Academy of Pharmaceutical Research and Science, American Pharmacists Association (APhA). From 2009-2010, Jim was President of ACCP.
Mechanisms, risk factors, prevention and management of drug-induced arrhythmias; Prevention and treatment of atrial fibrillation; Medication safety
Service and Engagement
Member, Board of Regents, American College of Clinical Pharmacy 2001-2004, 2008-2011
Chair, Clinical Sciences Section, Academy of Pharmaceutical Research & Science (APRS), American Pharmacists Association (APhA) 2008-2009
President, American College of Clinical Pharmacy, 2009-2010
Honors and Credentials
Board Certified Pharmacotherapy Specialist (BCPS)
Fellow, American College of Clinical Pharmacy
Fellow, American Pharmacists Association
Fellow, American Heart Association
Distinguished Practitioner and Fellow, National Academies of Practice
Heart Rhythm Society Atrial Fibrillation Awareness Program: Screening for Atrial Fibrillation in Community Pharmacies, September 1, 2016 - December 31, 2016
American Heart Association Midwest Affiliate: Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes, July 1, 2015 - June 30, 2017
American Heart Association Midwest Affiliate: Influence of Progesterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes, July 1, 2012 - December 31, 2014.
Indiana University Clinical Translational Sciences Institute (CTSI) Center of Excellence in Cardiovascular Research (CECARE) award. Sensitivity to drug-induced QT interval lengthening in patients with heart failure with preserved ejection fraction. November 1, 2012 - April 30, 2017.
American Heart Association: Mechanisms of Increased Risk of Torsades de Pointes Associated with Potassium Channel Blocking Agents in Heart Failure, January 1, 2004 - December 31, 2005.
Administration and Committee Work
Interim Head, Department of Pharmacy Practice, February 2012 - August 2014
Alburikan KA, Savitz ST, Whitsel EA, Tisdale JE, Soliman EZ, Thudium EM, Sueta CA, Kucharska-Newton AM, Stearns SC, Rodgers JE. Contributions of medications and risk factors to QT interval lengthening in the Atherosclerosis Risk in Communities (ARIC) Study. J Eval Clin Pract 2017 (In press).
Tisdale JE. Incidence and significance of acquired QT interval prolongation in hospitalized patients. Heart Rhythm 2017;14:979-980.
Tisdale JE, Jaynes JA, Overholser BR, Sowinski KM, Flockhart DA, Kovacs RJ. Influence of oral progesterone administration on drug-induced QT interval lengthening. A randomized, placebo-controlled crossover trial. JACC Clin Electrophysiol 2016;2:765-774.
Abdelhady AM, Shugg T, Thong N, Lu JBL, Kreutz Y, Jaynes HA, Robarge JD, Tisdale JE, Desta Z, Overholser BR. Efavirenz inhibits the human ether-a-go-go related current (hERG) and induces QT interval prolongation in CYP2B6*6*6 allele carriers. J Cardiovasc Electrophysiol 2016;27:1206-1213.
Melton BL, Zillich AJ, Saleem J, Russ AL, Tisdale JE, Overholser BR. Iterative development and evaluation of a pharmacogenomic-guided clinical decision support system for warfarin dosing. Appl Clin Inform 2016;7:1088-1106.
Tisdale JE. Drug-induced QT interval prolongation in children - are the kids alright? Can J Hosp Pharm 2016;69:183-184.
Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Can Pharm J 2016;149:139-152.
Tisdale JE, Allen MR, Overholser BR, Jaynes HA, Kovacs RJ. Influence of zoledronic acid on atrial electrophysiological parameters and electrocardiographic measurements. J Cardiovasc Electrophysiol 2015;26:671-677.
Frendl G, Sodickson AC, Chung MK, Waldo AL, Gersh BJ, Tisdale JE, Calkins H, Aranki S, Kaneko T, Cassivi S, Smith SC Jr, Darbar D, Wee JO, Waddell TK, Amar D, Adler D. 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. J Thorac Cardiovasc Surg 2014;148:e153-193.
Frendl G, Sodickson AC, Chung MK, Waldo AL, Gersh BJ, Tisdale JE, Calkins H, Aranki S, Kaneko T, Cassivi S, Smith SC Jr, Darbar D, Wee JO, Waddell TK, Amar D, Adler D. 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Executive summary. J Thorac Cardiovasc Surg 2014;148:772-791.
Tisdale JE. What causes some patients with drug-induced QT interval prolongation to develop torsades de pointes but not others? The elusive missing link. Drugs Aging 2014;31:577-579.
Tisdale JE. Can I get a guideline to help me interpret treatment guidelines? Can J Hosp Pharm 2014;67:181-182.
Tisdale JE, Jaynes HA, Kingery JR, Overholser BR, Mourad NA, Trujillo TN, Kovacs RJ. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 2014;7:381-390.
Trinkley KE, Page II RL, Lien H, Yamanouye K, Tisdale JE. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin 2013;29:1729-1736.
Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, Kovacs RJ. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 2013;6:479-487.
Mohamed AN, Abdelhady AM, Spencer D, Sowinski KM, Tisdale JE, Overholser BR. Pharmacokinetic modeling and simulation of procainamide and N-acetylprocainamide in a patient receiving continuous renal replacement therapy: a novel approach to guide renal dose adjustments (research letter). Am J Kidney Dis 2013;61:1046-1047.
Tisdale JE, Overholser BR, Sowinski KM, Wroblewski HA, Amankwa K, Borzak S, Coram R, Kingery J, Zipes DM, Flockhart DA, Kovacs RJ. Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction. J Clin Pharmacol 2012;52:1296-1305
Hall KW, Musing E, Miller DA, Tisdale JE. Experiential training for pharmacy students: time for a new approach. Can J Hosp Pharm 2012;65:285-293.
Kaakeh Y, Overholser BR, Lopshire J, Tisdale JE. Drug-induced atrial fibrillation. Drugs 2012;72:1617-1630.
Wroblewski HA, Kovacs RJ, Kingery JR, Overholser BR, Tisdale JE. High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for the treatment of resistant malaria or babesiosis. Antimicrob Agents Chemother 2012;56:4495-4499.
Tisdale JE, Wroblewski HA, Kingery JR, Overholser BR, Trujillo TN, Kovacs RJ. Prospective, observational study of the prevalence of QT interval prolongation in patients admitted to cardiac care units in a large urban medical center and frequency of subsequent administration of QT interval-prolonging drugs. Drug Saf 2012;35:459-470.
Fernando HC, Jaklitsch MT, Walsh GL, Tisdale JE, Bridges CD, Mitchell JD, Shrager JB. The Society of Thoracic Surgeons practice guideline on the prophylaxis and management of atrial fibrillation associated with general thoracic surgery: executive summary. Ann Thorac Surg 2011;92:1144-52.
Tisdale JE, Overholser BR, Wroblewski HA, Sowinski KM. The influence of progesterone alone and in combination with estradiol on ventricular action potential duration and triangulation in response to potassium channel inhibition. J Cardiovasc Electrophysiol 2011;22:325-331.
Tisdale JE, Wroblewski HA, Kesler KA. Prophylaxis of atrial fibrillation after noncardiac thoracic surgery. Semin Thorac Surg 2010;22:310-320.
Tisdale JE, Wroblewski HA, Wall DS, Rieger KM, Hammoud ZT, Young JV, Kesler KA. A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy. J Thorac Cardiovasc Surg 2010;140:45-51.
Tisdale JE, Miller DA. Drug-Induced Diseases. Prevention, Detection and Management, 2nd ed. Bethesda; American Society of Health-Systems Pharmacists: 2010.
Overholser BR, Zheng X, Tisdale JE. Paroxysmal β-adrenergic receptor mediated alterations in ventricular repolarization at rapid heart rates during inhibition of delayed rectifier currents. J Cardiovasc Pharmacol 2009;54:253-262.
Tisdale JE, Wroblewski HA, Wall DS, Rieger KM, Hammoud ZT, Young JV, Kesler KA. A randomized trial evaluating amiodarone for prevention of atrial fibrillation after pulmonary resection. Ann Thorac Surg 2009;88:886-895.
Tisdale JE, Overholser BR, Sowinski KM, Wroblewski HA, Amankwa K, Borzak S, Coram R, Kingery J, Zipes DM, Flockhart DA, Kovacs RJ. Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction. Pharmacotherapy 2008;28:1461-1470.
Overholser BR, Zheng X, Tisdale JE. Catecholaminergic effects on ventricular repolarization during inhibition of the rapid component of the delayed rectifier potassium current in a perfused heart model. Pharmacotherapy 2008;28:1315-1324.
Legreid-Dopp A, Miller JM, Tisdale JE. Effect of drugs on defibrillation capacity. Drugs 2008;68:607-630.
Tisdale JE, Wroblewski HA, Hammoud ZT, Rieger KM, Young JV, Wall DS, Kesler KA. Prospective evaluation of serum amiodarone concentrations when administered via a nasogastric tube into the stomach conduit after transthoracic esophagectomy. Clin Ther 2007;29:226-34.
Buckley MS, Nolan PE Jr, Slack MK, Tisdale JE, Hilleman DE, Copeland JG. Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation. Pharmacotherapy 2007;27:360-368.
Tisdale JE, Kovacs R, Mi D, McCabe GP, Cariera BL, Sharma N, Rosman H. Accuracy of uncorrected versus corrected QT interval for prediction of torsades de pointes associated with intravenous haloperidol. Pharmacotherapy 2007;27:175-82.
Tisdale, JE, Borzak S, Goldstein S, Shimoyama H, Sabbah HN. Hemodynamic and neurohormonal predictors and consequences of the development of atrial fibrillation in dogs with chronic heart failure. J Cardiac Fail 2006; 12:747-51.
Rasty S, Amin NB, Borzak S, Mishima T, Sabbah HN, Tisdale JE. Influence of IV haloperidol on ventricular repolarization and monophasic action potential duration in anesthetized dogs. Chest 2004 125:1821-1829.
Amankwa K, Krishnan CK, Tisdale JE. Torsades de pointes associated with fluoroquinolones. Importance of concomitant risk factors. Clin Pharmacol Ther 2004; 75:242-7.
Rasty S, Borzak S, Tisdale JE. Bleeding associated with eptifibatide targeting higher-risk patients: incidence and multivariate risk factors. J Clin Pharmacol 2002;42:1366-1373.
Tran AH, Yrigoyen LG, Racine E, Tisdale JE. Use of dofetilide in atrial fibrillation and atrial flutter. J Am Pharm Assoc 2001;41:747-759.
Slavik RS, Tisdale JE, Borzak S. Pharmacological conversion of atrial fibrillation: a systematic review of available evidence. Prog Cardiovasc Dis 2001;44:121-152.
Zed P, Tisdale JE, Borzak S. Low molecular weight heparins in acute coronary syndromes. Arch Intern Med 1999; 159:1849-1857.
Amin N, Borzak S, Housholder SA, Tisdale JE. Multiple episodes of sinus arrest following the administration of ibutilide in a patient with underlying sinus node dysfunction. Heart 1998;79:628-9.
Borzak S, Tisdale JE, Amin NB, Goldberg AD, Frank D, Padhi ID, Higgins RSD. Atrial fibrillation after bypass surgery. Does the arrhythmia or the characteristics of the patients prolong hospital stay? Chest 1998;113:1489-1491.
Tisdale JE, Padhi ID, Goldberg AD, Silverman NA, Webb CR, Higgins RS, Paone G, Frank DM, Borzak S. A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation following coronary artery bypass surgery. Am Heart J 1998; 135:739-747.
Sharma N, Rosman H, Padhi ID, Tisdale JE. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81:238-240.
Tisdale JE, Padhi ID, Ware JA, Svensson CK. Comparison of fluorescence polarization immunoassay with liquid chromatography for quantification of procainamide and N-acetylprocainamide in urine. Ther Drug Monit 1996;18:693-697.
Tisdale JE, Rudis MI, Padhi ID, Borzak S, Svensson CK, Webb CR, Acciaioli J, Ware JA, Krepostman A, Zarowitz BJ. Disposition of procainamide in patients with chronic congestive heart failure receiving medical therapy. J Clin Pharmacol 1996;36:35-41.
Tisdale JE, Rudis MI, Padhi ID, Svensson CK, Webb CR, Borzak S, Ware JA, Krepostman A, Zarowitz BJ. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans. J Clin Pharmacol 1995;35:902-910.
Tisdale JE, Patel R, Borzak S, Webb CR, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis 1995;38:167-180.
Tisdale JE, Patel R, Borzak S, Webb CR, Zarowitz BJ. Proarrhythmic effects of intravenous vasopressors. Ann Pharmacother 1995;29:269-281.
Tisdale JE, Kluger J, Fisher JR, Chow MSS. Efficacy of class 1C antiarrhythmic agents in patients with inducible ventricular tachycardia refractory to class 1A antiarrhythmic drugs. J Clin Pharmacol 1993;33:623-630.
Tisdale JE, Gheorghiade M. Acute hemodynamic effects of digoxin alone or in combination with other vasoactive agents in patients with heart failure. Am J Cardiol 1992;69:34G-47G.